22093-36-3

Usage

Chemical compound

1-Benzyl-4-butylpiperidin-4-ol

Class

Cathinone derivative

Physical appearance

White, crystalline powder

Administration methods

Snorting or oral ingestion

Effects

Euphoria, increased energy, enhanced focus

Comparison

Similar to amphetamines or cocaine

Risks

High potential for addiction and dependence

Health issues

Cardiovascular problems, psychosis

Legal status

Controlled substance in many countries, illegal for recreational use

Upstream product

• 109-72-8 n-butyllithium 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 693-04-9 butyl magnesium bromide 
• 88-65-3 2-bromobenzoic-acid 

Relevant academic research and scientific papers

Synthesis, pharmacological activity and structure affinity relationships of spirocyclic σ1 receptor ligands with a (2-fluoroethyl) residue in 3-position

In order to develop a fluorinated radiotracer for imaging of σ1 receptors in the central nervous system a series of (2-fluoroethyl) substituted spirocyclic piperidines 3 has been prepared. In the key step of the synthesis 2-bromocinnamaldehyde

Efficient synthesis of a highly selective NPY-5 receptor antagonist: A drug candidate for the treatment of obesity

A concise and practical synthesis of highly selective NPY-5 receptor antagonist 1 is described. The animopyrazine intermediate 3 was synthesized via either monobromination of aminopyrazine or palladium-catalyzed regioselective debromination of dibromopyrazine followed by an efficient Suzuki-Miyaura coupling. For the preparation of the spirolactone piperidine 2, significantly improved yield was achieved by using a combination of n-BuMgCl and n-BuLi. This protocol also dramatically increased the thermal stability of the aryllithium intermediate and eliminated the requirement for costly cryogenic conditions. The union of the spirolactone piperidine 2 and aminopyrazine 3 via a carbonyl group was accomplished using phenyl chloroformate delivering the target molecule in high yield.

Benzimidazolidinone derivatives as muscarinic agents

Benzimidazolidinone derivative compounds, which increase acetylcholine signaling or effect in the brain, and highly selective muscarinic agonists, particularly for the M1 and/or M4 receptor subtypes, pharmaceutical compositions comprising the same, as well as methods of treating psychosis using these compounds are disclosed.

Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting ERAB or HADH2 activity

Pyrazole compounds represented by the formula: are described. The pyrazole compounds and pharmaceutical compositions containing them may be used in inhibiting ERAB or HADH2 activity and in treating ERAB, HADH2 or amyloid-β mediated diseases and conditions